FEBRUARY 2014

Clinical Chemistry Contents

EDITORIALS

Circulating Tumor Cell Isolation: A Marathon Race Worth Running E.S. Lianidou (see article on page 323)	287
As If Biomarker Discovery Isn't Hard Enough: The Consequences of Poorly Characterized Reagents K.D. Rodland (see article on page 381)	290
PERSPECTIVE	
Genomic Test Validation for Incidental Findings J.Y. Park, P. Fortina, and L.J. Kricka	292
Q&A	
Biomarkers for Acute Kidney Injury: Where Are We Today? Where Should We Go? Moderator: J.C. Lieske; Experts: L. Chawla, K. Kashani, J.A. Kellum, J.L. Koyner, and R.L. Mehta	294
CLINICAL CASE STUDY	
Increased Serum Creatine Kinase M. Mirzazadeh, N. Maghsoodi, and J. Barron	301
COMMENTARIES	
C.E. Siskind	304
C.M. Lockwood	305
REVIEW	
The Potential Role of Oral Fluid in Antidoping Testing S. Anizan and M.A. Huestis	307
ARTICLES	
MOLECULAR DIAGNOSTICS AND GENETICS	
Flexible Micro Spring Array Device for High-Throughput Enrichment of Viable Circulating Tumor Cells R.A. Harouaka, MD. Zhou, YT. Yeh, W.J. Khan, A. Das, X. Liu, C.C. Christ, D.T. Dicker,	

T.S. Baney, J.T. Kaifi, C.P. Belani, C.I. Truica, W.S. El-Deiry, J.P. Allerton, and S.-Y. Zheng (see

editorial on page 287)

Influence of PCR Reagents on DNA Polymerase Extension Rates Measured on Real-Time PCR Instruments J.L. Montgomery and C.T. Wittwer

Volume 60, Number 2, Pages 287-431



Comparison of mRNA Splicing Assay Protocols across Multiple Laboratories: Recommendations for Best Practice in Standardized Clinical Testing P.J. Whiley, M. de la Hoya, M. Thomassen, A. Becker, R. Brandão, I.S. Pedersen, M. Montagna, M. Menéndez, F. Quiles, S. Gutiérrez-Enríquez, K. De Leeneer, A. Tenés, G. Montalban, D. Tserpelis, T. Yoshimatsu, C. Tirapo, M. Raponi, T. Caldes, A. Blanco, M. Santamariña, L. Guidugli, G. Ruiz de Garibay, M. Wong, M. Tancredi, L. Fachal, Y.C. Ding, T. Kruse, V. Lattimore, A. Kwong, T.L. Chan, M. Colombo, G. De Vecchi, M. Caligo, D. Baralle, C. Lázaro, F. Couch, P. Radice, M.C. Southey, S. Neuhausen, C. Houdayer, J. Fackenthal, T. Van Overeem Hansen, A. Vega, O. Diez, R. Blok, K. Claes, B. Wappenschmidt, L. Walker, A.B. Spurdle, and M.A. Brown on behalf of the ENIGMA consortium 341

DRUG MONITORING AND TOXICOLOGY

Calcineurin Activity Assay Measurement by Liquid Chromatography–Tandem Mass Spectrometry in the Multiple Reaction Monitoring Mode L. Carr, A.-L. Gagez, M. Essig, F.-L. Sauvage, P. Marquet, and L.N. Gastinel

Urinary Cannabinoid Disposition in Occasional and Frequent Smokers: Is THC-Glucuronide in Sequential Urine Samples a Marker of Recent Use in Frequent Smokers? N.A. Desrosiers, D. Lee, M. Concheiro-Guisan, K.B. Scheidweiler, D.A. Gorelick, and M.A. Huestis 361

HEMATOLOGY

Newborn Blood Spot Screening for Sickle Cell Disease by Using Tandem Mass Spectrometry: Implementation of a Protocol to Identify Only the Disease States of Sickle Cell Disease S.J. Moat, D. Rees, L. King, A. Ifederu, K. Harvey, K. Hall, G. Lloyd, C. Morrell, and S. Hillier

373

353

continued

Clinical Chemistry (ISSN 0009-9147) is published monthly by the American Association for Clinical Chemistry, 1850 K Street, NW, Suite 625, Washington, DC 20006. New subscriptions, renewals, changes of address, back issues, and all customer service questions should be addressed to: AACC, Subscription Department, 1850 K Street, NW, Suite 625, Washington, DC 20006. Telephone (202) 857-0717 or 1 (800) 892-1400; fax (202) 887-5093; e-mail custorery@aacc.org. Subscription rates: Institutional subscription USA \$1,229, elsewhere \$1,418. Individual subscription USA \$372, elsewhere \$575. Airmail delivery outside USA is an additional \$290. Individual subscriptions are for personal use and not to be used in a library. Periodicals postage paid at Washington, DC and at additional mailing offices. Postmaster: Send address changes to Clinical Chemistry, 1850 K Street, NW, Suite 625, Washington, DC 2006. Copyright © 2014 The American Association for Clinical Chemistry.

323

Clinical Chemistry Contents

	PROTEOMICS AND PROTEIN MARKERS	
20	False Biomarker Discovery due to Reactivity of a	
V	Commercial ELISA for CUZD1 with Cancer	
CA	Antigen CA125 I. Prassas, D. Brinc, S. Farkona,	
	F. Leung, A. Dimitromanolakis, C.C. Chrystoja, R. Brand, V. Kulasingam, I.M. Blasutig,	
	and E.P. Diamandis (see editorial on page 290)	381
	High-Sensitivity Troponin as a Predictor of Cardiac Events and Mortality in the Stable	
	Dialysis Population H.C. Hassan, K. Howlin,	
	A. Jefferys, S.T. Spicer, A.N. Aravindan,	
	G. Suryanarayanan, B.M. Hall, B.D. Cleland,	
	J.K. Wong, M.G. Suranyi, and A. Makris	389
	OTHER AREAS OF CLINICAL CHEMISTRY	
	Quality Markers Addressing Preanalytical Variations	
	of Blood and Plasma Processing Identified by Broad	
	and Targeted Metabolite Profiling B. Kamlage,	
	S. González Maldonado, B. Bethan, E. Peter, O. Schmitz, V. Liebenberg, and P. Schatz	399
	O. Schinitz, V. Elebenberg, and F. Schatz	393
.E1	TERS TO THE EDITOR	
.E1	More on Lot-to-Lot Changes R. Bais and D. Chesher	413
E1	More on Lot-to-Lot Changes R. Bais and D. Chesher DNA Concentration Can Specify DNA Melting Point	413
<u>E1</u>	More on Lot-to-Lot Changes R. Bais and D. Chesher DNA Concentration Can Specify DNA Melting Point in a High-Resolution Melting Analysis Master Mix	
ET	More on Lot-to-Lot Changes R. Bais and D. Chesher DNA Concentration Can Specify DNA Melting Point	
ET	More on Lot-to-Lot Changes R. Bais and D. Chesher DNA Concentration Can Specify DNA Melting Point in a High-Resolution Melting Analysis Master Mix J.W.S. Ng, D.C. Holt, P. Andersson, and P.M. Giffard Clinical Use of Reference Intervals Derived from	
81	More on Lot-to-Lot Changes R. Bais and D. Chesher DNA Concentration Can Specify DNA Melting Point in a High-Resolution Melting Analysis Master Mix J.W.S. Ng, D.C. Holt, P. Andersson, and P.M. Giffard Clinical Use of Reference Intervals Derived from Some CALIPER Studies Questioned V. Gounden and	414
ET	More on Lot-to-Lot Changes R. Bais and D. Chesher DNA Concentration Can Specify DNA Melting Point in a High-Resolution Melting Analysis Master Mix J.W.S. Ng, D.C. Holt, P. Andersson, and P.M. Giffard Clinical Use of Reference Intervals Derived from Some CALIPER Studies Questioned V. Gounden and S.J. Soldin	414
EI	More on Lot-to-Lot Changes R. Bais and D. Chesher DNA Concentration Can Specify DNA Melting Point in a High-Resolution Melting Analysis Master Mix J.W.S. Ng, D.C. Holt, P. Andersson, and P.M. Giffard Clinical Use of Reference Intervals Derived from Some CALIPER Studies Questioned V. Gounden and S.J. Soldin Interpretation of Cortisol Concentrations and	414
EI	More on Lot-to-Lot Changes R. Bais and D. Chesher DNA Concentration Can Specify DNA Melting Point in a High-Resolution Melting Analysis Master Mix J.W.S. Ng, D.C. Holt, P. Andersson, and P.M. Giffard Clinical Use of Reference Intervals Derived from Some CALIPER Studies Questioned V. Gounden and S.J. Soldin Interpretation of Cortisol Concentrations and Reference Intervals from the CALIPER Database	414 416
<u>E1</u>	More on Lot-to-Lot Changes R. Bais and D. Chesher DNA Concentration Can Specify DNA Melting Point in a High-Resolution Melting Analysis Master Mix J.W.S. Ng, D.C. Holt, P. Andersson, and P.M. Giffard Clinical Use of Reference Intervals Derived from Some CALIPER Studies Questioned V. Gounden and S.J. Soldin Interpretation of Cortisol Concentrations and	414 416
E	More on Lot-to-Lot Changes R. Bais and D. Chesher DNA Concentration Can Specify DNA Melting Point in a High-Resolution Melting Analysis Master Mix J.W.S. Ng, D.C. Holt, P. Andersson, and P.M. Giffard Clinical Use of Reference Intervals Derived from Some CALIPER Studies Questioned V. Gounden and S.J. Soldin Interpretation of Cortisol Concentrations and Reference Intervals from the CALIPER Database	414 416
3	More on Lot-to-Lot Changes R. Bais and D. Chesher DNA Concentration Can Specify DNA Melting Point in a High-Resolution Melting Analysis Master Mix J.W.S. Ng, D.C. Holt, P. Andersson, and P.M. Giffard Clinical Use of Reference Intervals Derived from Some CALIPER Studies Questioned V. Gounden and S.J. Soldin Interpretation of Cortisol Concentrations and Reference Intervals from the CALIPER Database C.R. Rovnaghi, A.F. Kala, S.L. Allen, and K.J.S. Anand	414 416 418
E	More on Lot-to-Lot Changes R. Bais and D. Chesher DNA Concentration Can Specify DNA Melting Point in a High-Resolution Melting Analysis Master Mix J.W.S. Ng, D.C. Holt, P. Andersson, and P.M. Giffard Clinical Use of Reference Intervals Derived from Some CALIPER Studies Questioned V. Gounden and S.J. Soldin Interpretation of Cortisol Concentrations and Reference Intervals from the CALIPER Database C.R. Rovnaghi, A.F. Kala, S.L. Allen, and K.J.S. Anand In Reply L. Kyriakopoulou, M. Yazdanpanah,	413 414 416 418 419
Ξ 1	More on Lot-to-Lot Changes R. Bais and D. Chesher DNA Concentration Can Specify DNA Melting Point in a High-Resolution Melting Analysis Master Mix J.W.S. Ng, D.C. Holt, P. Andersson, and P.M. Giffard Clinical Use of Reference Intervals Derived from Some CALIPER Studies Questioned V. Gounden and S.J. Soldin Interpretation of Cortisol Concentrations and Reference Intervals from the CALIPER Database C.R. Rovnaghi, A.F. Kala, S.L. Allen, and K.J.S. Anand In Reply L. Kyriakopoulou, M. Yazdanpanah, D. Colantonio, and K. Adeli On the Importance of Unconditional Rewards for Blood	414 416 418
ET	More on Lot-to-Lot Changes R. Bais and D. Chesher DNA Concentration Can Specify DNA Melting Point in a High-Resolution Melting Analysis Master Mix J.W.S. Ng, D.C. Holt, P. Andersson, and P.M. Giffard Clinical Use of Reference Intervals Derived from Some CALIPER Studies Questioned V. Gounden and S.J. Soldin Interpretation of Cortisol Concentrations and Reference Intervals from the CALIPER Database C.R. Rovnaghi, A.F. Kala, S.L. Allen, and K.J.S. Anand In Reply L. Kyriakopoulou, M. Yazdanpanah, D. Colantonio, and K. Adeli	414 416 418 419
.E1	More on Lot-to-Lot Changes R. Bais and D. Chesher DNA Concentration Can Specify DNA Melting Point in a High-Resolution Melting Analysis Master Mix J.W.S. Ng, D.C. Holt, P. Andersson, and P.M. Giffard Clinical Use of Reference Intervals Derived from Some CALIPER Studies Questioned V. Gounden and S.J. Soldin Interpretation of Cortisol Concentrations and Reference Intervals from the CALIPER Database C.R. Rovnaghi, A.F. Kala, S.L. Allen, and K.J.S. Anand In Reply L. Kyriakopoulou, M. Yazdanpanah, D. Colantonio, and K. Adeli On the Importance of Unconditional Rewards for Blood	414 416 418

In Reply J. Kreuter and M. Gandhi

424

CLINICAL CHEMIST WHAT IS YOUR GUESS? Glow Stick or Urine Sample? C.L. Henemyre-Harris, M. Samols, A.S. Wenick, and L.J. Sokoll 425 **NEWS & VIEWS** Be-(a)-ware of the Red Flags: Common Flaws of Nonreproducible Preclinical Research Studies N. Korpi-Steiner and R. Molinaro 427 Food and Drug Administration Starts Treating Mobile Medical Apps as Medical Devices T. Kampfrath 428 UNVEILING THE RIGHT SIDE Learning from Siddhartha E.P. Diamandis 429 SCIENCE IN THE ARTS A Different Body: Diagnostic Imaging and Body Art M.H. Dominiczak 430 **ACCENT®—CONTINUING EDUCATION CREDIT FOR**

ACCENT®—CONTINUING EDUCATION CREDIT FOR READERS OF CLINICAL CHEMISTRY

For more information go to http://www.aacc.org/applications/ccjaccent

continued

Clinical Chemistry Contents

Volume 60, Number 2, Pages 287–431 FEBRUARY 2014



ON THE COVER Baseball bat, ball, glove. Baseball, endearingly called America's Pastime, is played by millions of children and adults every year. Coaches teach each player to follow the advice of the sportswriter Henry Grantland Rice, who wrote, "It's not whether you win or

lose, it's how you play the game." Some individuals believe that this piece of advice has at its core the belief that "losing while playing fair is better than winning by cheating." Unfortunately, the desire to win at all costs has caused athletes to cheat by doping to enhance sport performance for centuries. The issue of doping arises again this month as the 2014 Winter Olympics begin. Currently, urine and blood are the only matrices authorized for antidoping testing by the World Anti-Doping Agency. Although the usefulness of urine and blood is proven in antidoping testing, issues remain for monitoring some drug classes and in cases involving drugs prohibited only in competition. The alternative matrix oral fluid may offer solutions to some of these issues. In this month's issue of Clinical Chemistry two scientists from the National Institute of Drug Abuse discuss the present state of knowledge, advantages and limitations of oral fluid testing, and the research needed to advance oral fluid testing as a viable alternative for antidoping testing. (See page 307.) ©Karen Shukle/Design Pics/Corbis. Reproduced with permission.

Technology Corner and color figures for Reviews sponsored by Department of Laboratory Medicine, Boston Children's Hospital.

Clinical Chemistry podcast coming soon to http://www.clinchem.org.

Individual articles may be selected to be a part of the Fast Track Program. Articles receive an expedited review, decision, and, if accepted, online publication.



Video available at http://www.clinchem.org.

Clinical Chemistry Journal Club

Selected articles made freely available, including helpful slides and key points for discussion in your Journal Club.

Circulating Proteolytic Products of Carboxypeptidase N for Early Detection of Breast Cancer Yaojun Li, Yueguo Li, Tao Chen, Anna S. Kuklina, Paul Bernard, Francisco J. Esteva, Haifa Shen, Mauro Ferrari, and Ye Hu

http://www.clinchem.org/content/60/1/233.full

Access the article by using the link above and by selecting Journal Club in the right-hand column.



Clinical Chemistry is now on Twitter, Facebook, and LinkedIn. Be a part of our community and receive updates on the latest issues, upcoming articles, podcasts, and more!



Clinical Chemistry apps available on iPhone, iPad, and Android.